申请人:Springer Caroline Joy
公开号:US20100298320A1
公开(公告)日:2010-11-25
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
本发明涉及治疗增生性疾病、癌症等的治疗化合物领域,更具体地涉及某些如下所述的吡啶并[2,3-b]吡嗪-8-取代化合物,其在其他方面抑制RAF(例如B-RAF)活性。本发明还涉及包含这种化合物的制药组合物,以及在体内外使用这种化合物和组合物,以抑制RAF(例如BRAF)活性,抑制受体酪氨酸激酶(RTK)活性,抑制细胞增殖,并用于治疗通过抑制RAF、RTK等所改善的疾病和疾病,如增生性疾病(例如结直肠癌、黑色素瘤)等。